/ 2 items

#TNYA↓

TNYA/ 03/05/2026 · 9:59 AM

Billion-Dollar Hearts: Tenaya and Alnylam Join Forces to Target Genetic Causes of Cardiovascular Disease

Tenaya Therapeutics partners with Alnylam to discover new genetic targets for heart disease treatments, potentially earning up to $1.13 billion in milestones.

TNYA/ 11/10/2025 · 6:46 AM

FDA Pauses Tenaya TN-201 Gene Therapy Trial for Standardization

The FDA placed a clinical hold on Tenaya’s TN-201 trial for MYBPC3-associated HCM to standardize immunosuppression patient management across sites. No delays expected.